Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms

Simple Summary In recent years, significant progress has been made in elucidating the mechanisms via which hepatocellular neoplasms, i.e., hepatocellular adenoma and hepatocellular carcinoma, arise. Hepatocellular carcinoma usually occurs in livers with chronic disease, due to deregulation of important intracellular pathways of signal transmission. Recent studies suggest that subclassification of hepatocellular carcinoma is practically useful. On the other hand, subclassification of hepatocellular adenomas has been well established through correlation of molecular alterations with morphology and protein expression. Advances in hepatic imaging have resulted in a new approach for diagnostic assessment of lesions arising in advanced chronic liver disease. Histologic examination, aided by immunohistochemistry, is the gold standard for the diagnosis and subclassification of hepatocellular neoplasms, while clinicopathologic correlation is essential for best patient management. We summarize the etiology and pathogenesis of hepatocellular neoplasms, provide practical information for their histologic diagnosis, and address various frequently asked questions regarding their diagnosis and practical implications. Abstract Hepatocellular carcinoma (HCC), a major global contributor of cancer death, usually arises in a background of chronic liver disease, as a result of molecular changes that deregulate important signal transduction pathways. Recent studies have shown that certain molecular changes of hepatocarcinogenesis are associated with clinicopathologic features and prognosis, suggesting that subclassification of HCC is practically useful. On the other hand, subclassification of hepatocellular adenomas (HCAs), a heterogenous group of neoplasms, has been well established on the basis of genotype–phenotype correlations. Histologic examination, aided by immunohistochemistry, is the gold standard for the diagnosis and subclassification of HCA and HCC, while clinicopathologic correlation is essential for best patient management. Advances in clinico-radio-pathologic correlation have introduced a new approach for the diagnostic assessment of lesions arising in advanced chronic liver disease by imaging (LI-RADS). The rapid expansion of knowledge concerning the molecular pathogenesis of HCC is now starting to produce new therapeutic approaches through precision oncology. This review summarizes the etiology and pathogenesis of HCA and HCC, provides practical information for their histologic diagnosis (including an algorithmic approach), and addresses a variety of frequently asked questions regarding the diagnosis and practical implications of these neoplasms.

[1]  X. Wang,et al.  Molecular pathogenesis and systemic therapies for hepatocellular carcinoma , 2022, Nature Cancer.

[2]  M. Kojima,et al.  Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis , 2022, Cancer science.

[3]  Jakob Nikolas Kather,et al.  Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. , 2022, Journal of hepatology.

[4]  Hepatocellular Neoplasms with Loss of Liver Fatty Acid Binding Protein: Clinicopathologic Features and Molecular Profiling. , 2022, Human pathology.

[5]  B. le Bail,et al.  Malignant transformation of hepatocellular adenoma , 2022, JHEP reports : innovation in hepatology.

[6]  C. Sempoux,et al.  Hepatocellular adenoma: what we know, what we do not know, and why it matters , 2021, Histopathology.

[7]  A. Luciani,et al.  Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy , 2021, Clinical Cancer Research.

[8]  Kathryn J Fowler,et al.  Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. , 2021, Radiographics : a review publication of the Radiological Society of North America, Inc.

[9]  G. Ioannou Epidemiology and risk-stratification of NAFLD-associated HCC. , 2021, Journal of hepatology.

[10]  V. Miller,et al.  Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma , 2021, JCO precision oncology.

[11]  Martijn P. D. Haring,et al.  Scoping review of clinical practice guidelines on the management of benign liver tumours , 2021, BMJ open gastroenterology.

[12]  K. Shanbhogue,et al.  Hepatocarcinogenesis: Radiology-Pathology Correlation. , 2021, Magnetic resonance imaging clinics of North America.

[13]  C. Balabaud,et al.  Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern! , 2021, Annals of surgery.

[14]  M. Yeh,et al.  Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification , 2021, Histopathology.

[15]  Seung‐Mo Hong,et al.  Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. , 2021, Asian journal of surgery.

[16]  J. Morelli,et al.  Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018 , 2021, Abdominal Radiology.

[17]  C. Sempoux,et al.  Predictive Patterns of Glutamine Synthetase Immunohistochemical Staining in CTNNB1-mutated Hepatocellular Adenomas , 2021, The American journal of surgical pathology.

[18]  Aurélie Beaufrère,et al.  Combined hepatocellular-cholangiocarcinoma: An update. , 2021, Journal of hepatology.

[19]  M. Torbenson Hepatocellular Carcinoma: Making Sense of Morphological Heterogeneity, Growth Patterns, and Subtypes. , 2020, Human pathology.

[20]  Johnny C. Hong,et al.  Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. , 2020, Journal of the American College of Surgeons.

[21]  L. Ny,et al.  Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection , 2020, Case Reports in Oncology.

[22]  Martijn P. D. Haring,et al.  A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[23]  C. Sempoux,et al.  ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice , 2020, Hepatology communications.

[24]  M. Ziol,et al.  Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma , 2020, Hepatology.

[25]  M. Ronot,et al.  Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular‐cholangiocarcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[26]  C. Sempoux,et al.  Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon , 2019, Modern Pathology.

[27]  J. Zucman‐Rossi,et al.  The role of telomeres and telomerase in cirrhosis and liver cancer , 2019, Nature Reviews Gastroenterology & Hepatology.

[28]  J. Zucman‐Rossi,et al.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. , 2019, Gastroenterology.

[29]  Kathryn J Fowler,et al.  cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation , 2018, Hepatology.

[30]  Sang Min Lee,et al.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging , 2018, European Radiology.

[31]  S. Kakar,et al.  13 – Tumours and Tumour-like Lesions of the Liver , 2018 .

[32]  M. Nikolski,et al.  Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk , 2017, Hepatology.

[33]  H. Tilg,et al.  Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma , 2017, Gut.

[34]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[35]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[36]  N. Heaton,et al.  Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series , 2017, Virchows Archiv.

[37]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[38]  M. Torbenson Morphologic Subtypes of Hepatocellular Carcinoma. , 2017, Gastroenterology clinics of North America.

[39]  P. Hytiroglou Well-differentiated hepatocellular nodule: Making a diagnosis on biopsy and resection specimens of patients with advanced stage chronic liver disease. , 2017, Seminars in diagnostic pathology.

[40]  S. Imbeaud,et al.  Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression , 2016, Hepatology.

[41]  Y. N. Park,et al.  Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization , 2016, Modern Pathology.

[42]  A. Luciani,et al.  Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis , 2016, Modern Pathology.

[43]  H. Reeves EASL Clinical Practice Guidelines on the management of benign liver tumours. , 2016, Journal of hepatology.

[44]  M. Torbenson,et al.  Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. , 2015, Human pathology.

[45]  B. Knudsen,et al.  Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma , 2015, Histopathology.

[46]  A. Sepulveda,et al.  HepPar-1 and Arginase-1 Immunohistochemistry in Adenocarcinoma of the Small Intestine and Ampullary Region. , 2015, Archives of pathology & laboratory medicine.

[47]  Y. Imai,et al.  Clinicopathological characteristics of serum amyloid A‐positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis , 2015, Histopathology.

[48]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[49]  J. Zucman‐Rossi,et al.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.

[50]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[51]  V. Vacic,et al.  Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.

[52]  J. Calderaro,et al.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[53]  S. Imbeaud,et al.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.

[54]  B. Naini,et al.  Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features , 2013, Modern Pathology.

[55]  R. Brody,et al.  An inflammatory proposal for hepatocarcinogenesis , 2012, Hepatology.

[56]  Angela M. Liu,et al.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.

[57]  Kevin Struhl,et al.  An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis , 2011, Cell.

[58]  Y. N. Park,et al.  Human hepatocellular carcinomas with “Stemness”‐related marker expression: keratin 19 expression and a poor prognosis , 2011, Hepatology.

[59]  B. Portmann,et al.  Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  N. Enomoto,et al.  Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation , 2011, Oncology.

[61]  G. Grazi,et al.  Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. , 2011, Journal of hepatology.

[62]  Q. Ye,et al.  Risk Factors, Prognosis, and Management of Early and Late Intrahepatic Recurrence After Resection of Primary Clear Cell Carcinoma of the Liver , 2011, Annals of Surgical Oncology.

[63]  J. Emond,et al.  Steatohepatitic Hepatocellular Carcinoma (SH-HCC): A Distinctive Histological Variant of HCC in Hepatitis C Virus-related Cirrhosis With Associated NAFLD/NASH , 2010, The American journal of surgical pathology.

[64]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[65]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[66]  Y. N. Park,et al.  The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. , 2009, Journal of hepatology.

[67]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[68]  Neil D Theise,et al.  Hepatic precancerous lesions and small hepatocellular carcinoma. , 2007, Gastroenterology clinics of North America.

[69]  Ning Zhang,et al.  Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy , 2007, World Journal of Surgery.

[70]  K. Schmitz,et al.  Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. , 2007, Journal of the American College of Surgeons.

[71]  F. Kondo,et al.  Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules , 2007, Cancer.

[72]  L. Terracciano,et al.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.

[73]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[74]  T. Okanoue,et al.  Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas , 2005, Gut.

[75]  M. Kojiro,et al.  Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy , 2004, Cancer Chemotherapy and Pharmacology.

[76]  Yoshiki Murakami,et al.  Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene , 2003, Oncogene.

[77]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[78]  P Neuhaus,et al.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.

[79]  Y. N. Park,et al.  “Vascular profiles” of regenerative and dysplastic nodules , 2000, Hepatology.

[80]  J. Crowe,et al.  Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. , 1999, European journal of gastroenterology & hepatology.

[81]  A. Wee,et al.  Combined Hepatocellular-Cholangiocarcinoma , 1999, Acta Cytologica.

[82]  Y. N. Park,et al.  Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. , 1998, The American journal of surgical pathology.

[83]  S. Thung,et al.  Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.

[84]  L. Ferrell,et al.  Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.

[85]  M. Tsuneyoshi,et al.  Spindle cell hepatocellular carcinoma: A clinicopathologic and immunohistochemical analysis of 15 cases , 1996, Cancer.

[86]  I. Wanless,et al.  Terminology of nodular hepatocellular lesions , 1995 .

[87]  S. Thung,et al.  Macroregenerative nodules in a series of adult cirrhotic liver explants: Issues of classification and nomenclature , 1995, Hepatology.

[88]  P. Brissot,et al.  Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients , 1993, Hepatology.

[89]  F. Callea,et al.  Pathology of hepatocellular carcinoma , 1993, Journal of surgical oncology. Supplement.

[90]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[91]  K. Okita,et al.  Morphologic studies of the liver cell dysplasia , 1983, Cancer.

[92]  J. V. Campos,et al.  [Hepatocellular adenoma]. , 2020, AMB : revista da Associacao Medica Brasileira.